- Home
- SAFE vs MLTX Comparison
SAFE vs MLTX Comparison
Compare SAFE & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | MLTX |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAFE | MLTX |
|---|---|---|
| Price | $15.60 | $15.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $18.80 | ★ $22.22 |
| AVG Volume (30 Days) | 373.0K | ★ 1.3M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.77% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | $0.98 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $9.33 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $5.95 |
| 52 Week High | $19.53 | $62.75 |
Technical Indicators
Market Signals| Indicator | SAFE | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 53.84 |
| Support Level | $14.43 | $15.27 |
| Resistance Level | $15.59 | $16.15 |
| Average True Range (ATR) | 0.46 | 0.74 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 70.77 | 66.14 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.